Clements C, Dhir S P, Grayston J T, Wang S P
Am J Ophthalmol. 1979 Mar;87(3):350-3. doi: 10.1016/0002-9394(79)90076-x.
A field trial of two high titer bivalent trachoma vaccines was done in a rural area of Northern India in children under the age of 6 years. Three months later 310 of the original 451 children in the study received a booster vaccination of either of the two vaccines or a placebo. Both the sucrose gradient purified and the Genetron purified vaccine protected against trachoma infection for one year. Significant protection for two years was found only with the gradient vaccine. A 12-year follow-up study located and examined 201 subjects that had received booster vaccine. It was found that 31, 27, and 28% of the individuals in each of the three groups (two vaccine and placebo) had evidence of mostly minimally active trachoma. Additionally, from 6 to 10% of the subjects in each group had signs of mild to moderate potentially blinding sequelae. The results showed no protection by either vaccine, and there was no evidence of adverse effects from the vaccines.
在印度北部农村地区,对6岁以下儿童进行了两种高滴度二价沙眼疫苗的现场试验。三个月后,研究中最初的451名儿童中有310名接受了两种疫苗之一或安慰剂的加强疫苗接种。蔗糖梯度纯化疫苗和Genetron纯化疫苗对沙眼感染均有一年的保护作用。仅梯度疫苗在两年内显示出显著的保护作用。一项为期12年的随访研究对接受加强疫苗接种的201名受试者进行了定位和检查。结果发现,三组(两种疫苗组和安慰剂组)中每组分别有31%、27%和28%的个体有大多为轻度活动性沙眼的迹象。此外,每组中有6%至10%的受试者有轻度至中度潜在致盲后遗症的迹象。结果显示两种疫苗均无保护作用,也没有证据表明疫苗有不良反应。